Vascular signaling pathways in the metabolic syndrome

Current Hypertension Reports

Volumn 4, Issue 2, 2002, Pages 105-111

  Rakugi, Hiromi ^a   Kamide, Kei ^a   Ogihara, Toshio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SYNDROME; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN RESISTANCE; METABOLIC DISEASES; MUSCLE, SMOOTH, VASCULAR; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SIGNAL TRANSDUCTION; SYNDROME;

EID: 0036546675     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-002-0034-1     Document Type: Article

References (64)

1. Reaven GM: Role of insulin resistance in human disease (syndrome X): an expanded definition. Ann Rev Med 1993, 44:121-131.
2. Kaplan NM: The deadly quartet and the insulin resistance syndrome: an historical overview. Hypertens Res 1996, 19:S9-11.
3. Matsuzawa Y, Shimomura I, Nakamura T., et al.: Pathophysiology and pathogenesis of visceral fat obesity. Ann N Y Acad Sci 1993, 676:270-278.
4. Ramos F, Baglivo HP, Ramirez A.J., et al.: The metabolic syndrome and related cardiovascular risk. Curr Hypertens Rep 2001, 3:100-106.
5. Kamide K, Nagano M, Nakano N., et al.: Insulin resistance and cardiovascular complications in patients with essential hypertension. Am J Hypertens, 1996, 9:1165-1171.
6. Kamide K, Rakugi H, Nakano N., et al.: Insulin resistance is related to silent cerebral infarction in patients with essential hypertension. Am J Hypertens 1997, 10:1245-1249.
7. Kadowaki T, Tobe K, Honda-Yamamoto R, et al.: Signal transduction mechanism of insulin and insulin-like growth factor-1. Endocrinol J 1996, 43:S33-S41.
8. Abe H, Yamada N, Kamata K., et al.: Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 1998, 101:1784-1788.
9. Kuboki K, Jiang ZY, Takahara N, et al: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000, 101:676-681.
10. Yamauchi TK, Tobe H, Tamemoto T., et al.: Insulin signaling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. Mol Cell Biol 1996, 16:3074-3084.
11. Ogihara T, Asano T, Ando K., et al.: Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats. Diabetes 2001, 50:573-583.
12. Nawano M, Ueta K, Oku A., et al.: Hyperglycemia impairs the insulin signaling step between PI 3-kinase and Akt/PKB activations in ZDF rat liver. Biochem Biophys Res Commun 1999, 266:252-256.
13. Oku A, Nawano M, Ueta K., et al.: Inhibitory effect of hyper-glycemia on insulin-induced Akt/protein kinase B activation in skeletal muscle. Am J Physiol Endocrinol Metab 2001, 280:E816-E824.
14. Griendling KK, Ushio-Fukai M: Reactive oxygen species as mediators of angiotensin II signaling. Regul Peptide 2000, 91: 21-27.
15. Blair AS, Hajduch E, Litherland G.J., et al.: Regulation of glucose transport and glycogen synthesis in L6 muscle cells during oxidative stress. Evidence for cross talk between the insulin and SAPK2/p38 mitogen-activated protein kinase signaling pathways. J Biol Chem 1999, 274:36293-36299.
16. Hansen LL, Ikeda Y, Olsen G.S., et al.: Insulin signaling is inhibited by micromolar concentrations of H2O2.: Evidence for a role of H2O2 in tumor necrosis factor alpha-mediated insulin resistance. J Biol Chem 1999, 274:25078-25084.
17. Rudich A, Tirosh A, Potashnik R., et al.: Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 1998, 47:1562-1569.
18. Kamide K, Kida I, Nagai M., et al.: Oxidative stress inhibits insulin signal transduction in cultured human vascular smooth muscle cells: A possible contribution to mechanism of insulin resistance [abstract]. Am J Hypertens 2001, 14(Part 2):25A.
19. Matsuzawa Y Funahashi T, Nakamura T: Molecular mechanism of metabolic syndrome X: contribution of adipocyto-kines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999, 892:146-154.
20. Yamauchi T, Kamon J, Waki H., et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
21. Berg AH, Combs TP, Du X, et al: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2000, 7:947-953.
22. Shimomura I, Funahashi T, Matsuzawa Y Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996, 2:800-803.
23. Steppan CM, Bailey ST, Bhat S, et al: The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
24. Goetze S, Xi XP, Kawano Y et al.: TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension 1999, 33:183-189.
25. Goetze S, Kintscher U, Kawano H., et al.: Tumor necrosis factor alpha inhibits insulin-induced mitogenic signaling in vascular smooth muscle cells. J Biol Chem 2000, 275:18279-18283.
26. Itoh H, Doi K, Tanaka T., et al.: Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma. Clin Exp Pharmacol Physiol 1999, 26:558-560.
27. Togashi N, Ura N, Higashiura K., et al.: The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hypertens 2000, 18:1605-1610.
28. Goetze S, Kim S, Xi X.P., et al.: Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells. J Cardiovasc Pharmacol 2000, 35:749-757.
29. Barroso IM, Gurnell VE, Crowley A, et al: Dominant negative mutations in human PPAR-gamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402:880-883.
30. Rett K: The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome. Diabetes Obes Metab 1999, 1:S8-S16.
31. Hsueh WA, Jackson S, Law RE: Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001, 24:392-397.
32. Plutzky J: Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep 2000, 2:327-335.
33. Kato K, Satoh K, Endo H.Y., et al.: Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPAR-gamma in endothelial function. Biochem Biophys Res Commun 1999, 258:431-435.
34. Marx N, Schonbeck U, Lazar M.A., et al.: Peroxisome proliferator- activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998, 83:1097-1103.
35. Nagy L, Tontonoz PJ, Alvarez G, et al: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998, 93:229-240.
36. Chawla A, Barak Y, Nagy L., et al.: PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001, 7:48-52.
37. Okuno A, Tamemoto H, Tobe K., et al.: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998, 101: 1354-1361.
38. Baron AD: Insulin and the vasculature-old actors, new roles. J Invest Med 1996, 44:406-412.
39. Begum N, Ragolia L, Rienzie J., et al.: Regulation of mitogen-activated protein kinase phosphatase-1 induction by insulin in vascular smooth muscle cells. Evaluation of the role of the nitric oxide signaling pathway and potential defects in hypertension. J Biol Chem 1998, 273:25164-25170.
40. Begum N, Ragolia L: High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation. Am J Physiol Cell Physiol 2000, 278:C81-C91.
41. Sandu OA, Ragolia L, Begum N: Diabetes in the Goto-Kakizaki rat is accompanied by impaired insulin-mediated myosin-bound phosphatase activation and vascular smooth muscle cell relaxation. Diabetes 2000, 49:2178-2189.
42. Saito F, Hori MT, Fittingoff M, et al: Insulin attenuates agonist-mediated calcium mobilization in cultured rat vascular smooth muscle cells. J Clin Invest 1993, 92:1161-1167.
43. Dick GM, Sturek M: Effects of a physiological insulin concentration on the endothelin-sensitive Ca2+ store in porcine coronary artery smooth muscle. Diabetes 1996, 45:876-880.
44. Igarashi M, Yamaguchi H, Hirata A., et al.: Insulin activates p38 mitogen-activated protein (MAP) kinase via a MAP kinase kinase (MKK) 3/MKK 6 pathway in vascular smooth muscle cells. Eur J Clin Invest 2000, 30:668-677.
45. Nagai M, Kamide K, Rakugi H., et al.: The role of endothelin-1 produced by insulin in the regulation of cell growth and renin-angiotensin system in endothelial cells [abstract]. Am J Hypertens 2001, 14(Part 2):224A.
46. Jiang ZY, Zhou QL, Chatterjee A, et al: Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. Diabetes 1999, 48:1120-1130.
47. Sano H, Higashi T, Matsumoto K., et al.: Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products. J Biol Chem 1998, 273:8630-8637.
48. Iimura O, Shimamoto K, Matsuda K., et al.: Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 1995, 8:353-357.
49. Schiffrin EL, Deng LY, Larochelle P: Progressive evaluation in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Am J Hypertens 1995, 8:229-236.
50. Schiffrin EL: Correlation of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000, 101:1653-1659.
51. Nawano M, Anai M, Funaki M., et al.: Imidapril, an angio-tensin- converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. Metabolism 1999, 48:1248-1255.
52. Higashiura K, Ura N, Takada T., et al.: The effects of an angio-tensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens 2000, 13:290-297.
53. Kamide K, Hori MT, Zhu J.H., et al.: Insulin-mediated growth in aortic smooth muscle and the vascular renin-angiotensin system. Hypertension 1998, 32:482-487.
54. Kamide K, Hori MT, Tuck M.L., et al.: Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells. J Hypertens 2000, 18:1051-1056.
55. Villette-Bounoua F.P., Eggena P, Barrett J.D., et al.: Intracrine production of angiotensin II in cultured VSMC is initiated by insulin and inhibited by lisinopril and omapatrilat [abstract]. Am J Hypertens 2001, 14(Part 2):19A.
56. Nickenig G, Roling J, Strehlow K., et al.: Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998, 98:2453-2460.
57. Kamide K, Rakugi H, Takiuchi S., et al.: Insulin-mediated modulation of the renin-angiotensin system in cultured human vascular endothelial cells [abstract]. J Hypertens 2000, 18:S11.
58. Kobayashi R, Nagano M, Nakamura F., et al.: Role of angiotensin II in high fructose-induced left ventricular hypertrophy in rats. Hypertension 1993, 21:1051-1055.
59. Kamide K, Rakugi H, Higaki J., et al.: The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose fed rats. Am J Hypertens 2001, In press.
60. Iyer SN, Raizada MK, Katovich MJ: AT1 receptor density changes during development of hypertension in hyper-insulinemic rats. Clin Exp Hypertens 1996, 18:793-810.
61. Folli F, Kahn CR, Hansen H, et al: Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/ angiotensin II cross talk. J Clin Invest 1997, 100:2158-2169.
62. Richey JM, Ader M, Moore D., et al.: Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol 1999, 277:E920-E926.
63. Baudry A, Lamothe B, Bucchini D., et al.: IGF-1 receptor as an alternative receptor for metabolic signaling in insulin receptor-deficient muscle cells. FEBS Lett 2001, 488:174-178.
64. Scheidegger KJ, Du J, Delafontaine P: Distinct and common pathways in the regulation of insulin-like growth factor-1 receptor gene expression by angiotensin II and basic fibroblast growth factor. J Biol Chem 1999, 274:3522-3530.